1. Introduction {#sec1}
===============

Maintenance of appropriate size and composition of both stem cell and progenitor cell pool is tightly regulated by continuous responding to surrounding and long-range orchestrating signals. Interestingly, sex hormones appeared lastly as important regulators of hematopoietic stem/progenitor cells (HSPCs) proliferation \[[@B1]\]. Recently, Nakada and colleagues revealed that hematopoietic stem cells (HSCs) expressed high levels of estrogen receptor and the administration of estradiol increased HSC cell division and self-renewal \[[@B2]\]. In support of this notion, murine HSPCs along with very small embryonic-like stem cells (VSELs) were also recently demonstrated to express receptors for pituitary-derived sex hormones, namely, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) \[[@B3]\]. In concert with this finding, murine HSPCs and VSELs following either*in vitro* or*in vivo* FSH and LH stimulation presented with high proliferative response as evidenced by BrdU incorporation. In the light of above mentioned observations, it is tempting to hypothesize the existence of developmental link between HSCs and VSELs and primordial germ cells (PGCs) that are naturally responsive to sex hormones \[[@B4], [@B5]\].

To date, however, it remained unknown whether the fact that stem cells are susceptible to signaling mediated by sex hormones can be used for mobilization of these cells in clinical settings. Moreover, based on the currently available scarce data, it is difficult to speculate if therapies using sex hormones will affect only fate of primordial stem cells and HSCs or rather would exert their actions toward all progenitor cell populations. Therefore, in the current study, we wished to investigate the effects of FSH therapy at clinically applied doses on mobilization of HSCs and VSELs as well as populations of endothelial progenitor cells (EPCs). In this study, EPCs were chosen as an example of easily identifiable, highly differentiated, and relatively numerous progenitor cell populations that account for endothelial repair and thus largely contribute to maintenance of appropriate vasculature \[[@B6]--[@B8]\]. On the other hand, quantification of decreased numbers of EPCs was found to improve prognostication of cardiovascular diseases (CVD) \[[@B9]--[@B11]\]. Thus, the search for therapeutic approaches aimed at efficient mobilization of functional EPCs is continuously warranted.

Here we tested in human model the actions of widely accepted regimens of FSH treatment with regard to three stem/progenitor cell subsets at different developmental hierarchy and differentiation level, namely, VSELs, HSCs, and EPCs. Moreover, given the previous reports indicating the crucial role of stroma derived factor-1 (SDF-1) for mobilization of stem cells \[[@B12]--[@B14]\], we set out to analyze whether any actions of clinically applied gonadotropins could affect not only stem cells and progenitor cells but also mediators regulating their migratory pathways.

2. Material and Methods {#sec2}
=======================

2.1. Patients and FSH Stimulation {#sec2.1}
---------------------------------

For the purpose of the study we recruited fifteen women aged 32.9 ± 3.9 years (range: 27--39 years) who were prepared for*in vitro* fertilization and underwent controlled FSH ovarian stimulation. FSH stimulation has been initiated on 3rd day of menstrual cycle and FSH dose was adjusted based on patient age, ovarian reserve, and previous response to FSH stimulation (if performed). Only two patients received stimulation based on combination of FSH and LH. EDTA-anticoagulated peripheral blood was collected twice: before FSH ovarian stimulation (or in five cases within first days of such stimulation) and at the end of FSH stimulation (days 7--11). Mean daily dose of FSH (either Gonal F, Merck Serono, or Puregon, Schering, or, in two patients, Menopur, Ferring) was 194.4 IU. Detailed characteristics of hormonal status of analyzed patients are presented in [Table 1](#tab1){ref-type="table"}.

All patients\' samples were collected upon the approval of Ethics Committee of the Medical University of Bialystok.

2.2. Extracellular Staining and Flow Cytometry {#sec2.2}
----------------------------------------------

170 *μ*L of fresh EDTA-anticoagulated whole blood was stained with the set of murine anti-human monoclonal antibodies described in detail in [Table 2](#tab2){ref-type="table"}. Samples were incubated for 30 min at room temperature in the dark. Thereafter, 2 mL of FACS lysing solution (BD) was added, followed by 15 min incubation in the dark. Cells were washed twice with cold PBS (phosphate-buffered saline) and fixed with CellFix (BD Biosciences). Appropriate fluorescence-minus-one (FMO) controls were used for setting compensation and for assuring correct gating. The gating strategy for HSCs and VSELs is shown in [Figure 1](#fig1){ref-type="fig"}, while gating strategy for identifying CD34^+^ cells and EPCs is presented in [Figure 2](#fig2){ref-type="fig"}. Samples were acquired using FACSCalibur flow cytometer (BD Biosciences). Obtained data were analyzed using FlowJo version 7.6.5 software (Tree Star).

2.3. Enzyme-Linked Immunosorbent Assays {#sec2.3}
---------------------------------------

SDF-1 plasma levels were quantified by means of commercially available enzyme-linked immunosorbent assays (ELISA, DuoSet, R&D). Samples were directly assayed according to manufacturer\'s instructions. The protein levels in the specimens were calculated from a reference curve generated by using reference standards. The detection range of used ELISA set was between 7,81 and 500 pg/mL. The samples were analyzed with automated light absorbance reader (LEDETEC 96 system). Results were calculated by MicroWin 2000 software.

2.4. Statistics {#sec2.4}
---------------

Statistical analysis was carried out using GraphPad Prism 6 (GraphPad software). Wilcoxon test was used. The differences were considered statistically significant at *p* \< 0.05. The results are presented as medians (interquartile range).

3. Results {#sec3}
==========

First, we analyzed the effects of FSH administration on the frequencies of circulating HSCs ([Figure 3(a)](#fig3){ref-type="fig"}). We found that FSH treatment resulted in statistically significant increase in Lin^−^CD133^+^CD45^+^ HSC numbers ((from 125.5 (66--133.5) to 175.5 (83.5--428.8) cells per 170 *μ*L of whole blood), *p* = 0.0303). Similarly, FSH treatment led to significant enhancement of Lin^−^CD133^+^CD45^−^  VSEL levels ([Figure 3(b)](#fig3){ref-type="fig"}). Following FSH therapy, VSEL numbers increased from 4 cells (3--11,5) to 34 cells (16,5--57) per 170 *μ*L of whole blood (*p* = 0.0057).

Next, we set out to investigate the influence of FSH administration on the frequencies of entire population of CD34^+^ cells and the population of EPCs delineated by such phenotypes as CD34^+^CD144^+^, CD34^+^CD133^+^, and CD34^+^CD133^+^CD309^+^ cells. Notably, we did not observe any significant changes in the numbers of single CD34^+^ cells following FSH administration ([Figure 4(a)](#fig4){ref-type="fig"}). Similarly, we did not demonstrate any significant changes in numbers of EPCs identified as CD34^+^CD144^+^ cells ([Figure 4(b)](#fig4){ref-type="fig"}), CD34^+^CD133^+^ cells ([Figure 4(c)](#fig4){ref-type="fig"}), and CD34^+^CD133^+^CD309^+^ cells ([Figure 4(d)](#fig4){ref-type="fig"}).

Finally, we wished to investigate whether FSH administration affected serum levels of SDF-1, one of crucial mobilizing factors for VSELs and HSCs ([Figure 5](#fig5){ref-type="fig"}). However, we did not find any significant change in SDF-1 concentrations upon completion of FSH administration (*p* \> 0.05).

4. Discussion {#sec4}
=============

Here we demonstrated that administration of pituitary-derived sex hormones at clinically applied doses allowed for efficient mobilization of frequencies of VSELs and HSCs but not endothelial progenitor cells. These findings build a platform for developing novel sex-hormone- based therapeutic strategies aimed at enhancement of either VSELs or HSCs numbers in conditions that would require efficient mobilization of these cells subsets.

Notably, it was shown that the links between gonadotropin hormones and stem cells may extend far beyond the effects exerted on VSELs and HSCs. Tadokoro and colleagues showed that FSH was one of crucial regulators of germinal stem cell (GSC) fate \[[@B15]\]. FSH regulated homeostatic control of glial cell line-derived neurotrophic factor (GDNF) which in turn accelerated proliferation of GSCs. These findings indicated that regulation of GCS population size is regulated by the GDNF/FSH pathway. It remains to be established whether effects of FSH treatment on VSELs and HSCs were related to actions mediated by GDNF. Recently, in concert with this notion, Tourkova and colleagues demonstrated that mesenchymal stem cells (MSC) expressing FSH-R responded with adhesion and proliferation following addition of FSH \[[@B16]\]. Moreover, short-term treatment by FSH at doses comparable to those observed in menopause augmented MSC proliferation by affecting signaling associated with Erk1/2 phosphorylation.

It remains elusive whether mobilizing effects of FSH/LH therapy on VSELs and HSCs in female patients were related to their direct effects on bone marrow-derived stem cells or rather on mobilization of stem cells localized in ovaries. On the other hand, both possibilities do not have to be mutually exclusive. Previously, it was demonstrated that stem cells found in ovaries have the phenotype of VSELs and they can give rise to more differentiated ovarian GCS \[[@B17], [@B18]\]. This was confirmed by later studies by Parte and colleagues who demonstrated that VSELs and GSCs were present in ovary surface epithelium (OSE) \[[@B19]\]. In this study, FSH treatment resulted in prominent proliferation of stem cell-harboring OSE and release of functional stem cells from ovaries. Moreover, Patel and colleagues found that FSH treatment resulted in increased clonal expansion of ovary-associated stem cells (both VSELs and ovarian GCSs), while FSH receptors were expressed only on ovarian stem cells but not on ovarian epithelial cells \[[@B20]\]. Similarly, Sriraman and colleagues showed that PMSG (FSH analog) increased VSELs numbers in chemoablated female mice \[[@B21]\]. Nevertheless, the question of how effects of gonadotropin hormones on stem cell population size are related to ovaries would require enrollment of male patients subjected to therapy with FSH and/or LH, the condition that due to ethical reasons certainly could not be achieved in the settings of the current study.

Notably, in our study, we did not demonstrate any significant effects of gonadotropin therapy on the levels of EPCs. In concert with this notion, in a representative group of patients with inflammatory bowel disease, Garolla and colleagues did not find relationships between levels of FSH or LH and numbers of EPCs \[[@B22]\]. In some contrast, however, reduced numbers of EPCs were found in hypogonadotropic hypogonadal male patients presenting with low levels of FSH and LH \[[@B23]\]. Interestingly, receptor for FSH is expressed by the endothelium of blood vessels in the majority of metastatic tumors \[[@B24]\]. Therefore, despite lack of significant effects of gonadotropin therapy on numbers of circulating EPCs analyzed in the current study, the subject of mutual relationships among EPCs, endothelial cells, and pituitary-derived sex hormones certainly deserves further investigation.

Our findings also bring about an interesting perspective for understanding relationships between stem and progenitor cells and elevated levels of FSH and LH that are detected at elderly age. In the light of our data, it is tempting to hypothesize that enhanced FSH and LH levels in elderly individuals could represent the mechanism of enhancing otherwise diminished hematopoiesis and decreased stem cell numbers. Similarly, this observation was previously documented in mouse model, wherein the numbers of VSELs were shown to be highest in young subjects and decreased with age \[[@B25]\].

Given these data, FSH and LH therapy could become an attractive and easily available tool enabling mobilization of stem cells in regenerative medicine. However, given the broad spectrum of the effects exerted by sex hormones, the safety of such approach would need to be examined in further clinical studies performed in different groups of patients including males. One has to keep in mind that FSH and LH were found to be involved in the growth of certain tumors. As an example, Ji and colleagues found significantly higher levels of mRNA encoding receptor for FSH (FSHR) in invasive ovarian tumors compared to low malignant tumors and normal OSE \[[@B26]\]. Similarly, it was reported that overexpression of FSHR in OSE cells led to an increase in expression of proteins involved in ovarian cancer development such as EGFR, c-myc, and HER2/neu. Thus any therapeutic strategies aimed at enhancement of the size of stem/progenitor cell pool by the use of gonadotropin-based therapies would need to be carefully investigated in terms of clinical safety.

Altogether, our data support recent findings on the role of FSH in the biology of VSELs and HSCs that were reported by our group in mouse model \[[@B4]\]. Thus, these data support a concept of a developmental link between germ line, VSELs, and hematopoiesis \[[@B4], [@B5]\]. Finally, we demonstrated here for the first time that mobilization of stem cells with VSELs phenotype and HSPCs can be achieved by the use of widely available therapeutic regimens based on pituitary-derived sex hormones.
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![Representative FACS plots demonstrating gating strategy for HSC and VSELs. First, 2--4 *μ*m size events were gated based on a forward and side scatter (FSC/SSC) dot plot (a). Then the 2--4 *μ*m gate was visualized on sample data using a FSC/SSC dot plot (b). Next, 2--4 *μ*m events were displayed on histogram plot (black peak, FMO control; grey peak identifies positive staining) and Lin^−^CD235a^−^ events were gated (c). Finally, FMO control was used to set the HSC and VSELs gate and exclude the background noise (d). Next, HSCs were defined as Lin^−^CD235a^−^CD45^+^CD133^+^ cells (upper gate) and VSELs were referred to as Lin^−^CD235a^−^CD45^−^CD133^+^ cells (e).](SCI2016-8530207.001){#fig1}

![Representative FACS plots demonstrating the gating strategy for CD34^+^ cells and EPCs. PBMCs were gated based on forward and side scatter (FSC/SSC) plot (b). CD34^+^ cells were gated on CD34/SSC plot (c). CD34^+^CD144^+^ cells (upper right quadrant, Q2) were gated based on CD34/CD144 dot plot (d). FMO control was used to set the gates (a). In order to determine CD34^+^CD144^+^CD309^+^ cell numbers, the PBMC events were displayed on the basis of FMO control sample (e) and gates were set to exclude the random noise. Next, the gates were visualized on CD34/CD133 plot (f) and CD34^+^CD133^+^ cells were gated (upper right quadrant, Q2). Finally, CD34^+^CD133^+^CD309^+^ cells subsets were gated on histogram plot (g) (black peak, control; grey peak, positive staining).](SCI2016-8530207.002){#fig2}

![Summary of analyses of time-course changes of the numbers of HSCs (a) and VSELs (b) during FSH therapy.](SCI2016-8530207.003){#fig3}

![Summary of analyses of time-course changes of the numbers of CD34^+^ cells (a), CD34^+^CD144^+^cells (b), CD34^+^CD133^+^ cells (c), and CD34^+^CD133^+^CD309^+^ cells (d) in the course of FSH therapy.](SCI2016-8530207.004){#fig4}

![Time-course analysis of individual changes in serum levels of SDF-1 in the course of FSH therapy.](SCI2016-8530207.005){#fig5}

###### 

The clinical and hormonal characteristics of female patients (*n* = 15) subjected to FSH stimulation.

  Studied parameter                                  Mean    SD     Minimum   Maximum
  -------------------------------------------------- ------- ------ --------- ---------
  Age (years)                                        32.9    3.9    27        39
  Duration of stimulation (days)                     8.8     1.1    8         11
  Mean daily dose of FSH (IU)                        194.4   43.8   120       262.5
  Number of mature follicles after FSH stimulation   10.9    3.4    5         16
  Estradiol at 7th day (pg/mL)                       1153    405    540       1684
  Progesterone at 7th day (ng/mL)                    0.5     0.15   0.25      0.67
  LH at 7th day (mIU/mL)                             1.1     0.67   0.31      2.33
  Estradiol at the last day (pg/mL)                  2314    1367   1367      3294
  Progesterone at the last day (ng/mL)               0.8     0.33   0.32      1.52
  LH at the last day (mIU/mL)                        1.7     0.85   0.72      2.97

###### 

Detailed characteristics of monoclonal antibodies used in the study.

  Name                                    Clone      Isotype   Format   Additional information                                                                                                                         Manufacturer
  --------------------------------------- ---------- --------- -------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Mouse anti-human anti-CD34              8G12       IgG1      FITC     This antibody binds to 105--120 kDa single-chain transmembrane glycoprotein, IVD                                                               Becton Dickinson
  Anti-human lineage cocktail 2 (lin 2)                        FITC                                                                                                                                                    Becton Dickinson
   Mouse anti-human anti-CD3              SK7        IgG1               This antibody binds to epsilon chain of the CD3 antigen, IVD                                                                                    
   Mouse anti-human anti-CD19             SJ25C1     IgG1               This antibody recognizes a 90 kDa antigen, IVD                                                                                                  
   Mouse anti-human anti-CD20             L27        IgG1               This antibody binds to phosphoprotein with a molecular weight of 35 or 37 kilodaltons (kDa), depending on the degree of phosphorylation, IVD    
   Mouse anti-human anti-CD14             M~*φ*~P9   IgG2b              This antibody reacts with a 53--55 kDa glycosylphosphatidylinositol- (GPI-) anchored and single chain glycoprotein, IVD                         
   Mouse anti-human anti-CD56             NCAM16.2   IgG2b              This antibody recognizes a heavily glycosylated 140 kDa isoform of NCAM, a member of the immunoglobulin (Ig) superfamily, IVD                   
  Mouse anti-human anti-CD235a            GA-R2      IgG2b     FITC     This antibody binds to glycophorin A, a sialoglycoprotein present on human red blood cells (RBC) and erythroid precursor cells                 Becton Dickinson
  Mouse anti-human anti-CD45              HI30       IgG1      PE       This antibody binds to 190, 190, 205, and 220 kDa protein isoforms, RUO                                                                        Becton Dickinson
  Mouse anti-human anti-CD144             55-7H1     IgG1      PE       This antibody reacts with calcium-independent epitope on cadherin 5, RUO                                                                       Becton Dickinson
  Mouse anti-human anti-CD309             89106      IgG1      PE       This antibody reacts with CD309 (vascular endothelial growth factor receptor-2 (VEGFR-2))                                                      Becton Dickinson
  Mouse anti-human anti-CD133             AC133      IgG1      APC      This antibody reacts with epitope 1 of CD133, RUO                                                                                              Miltenyi Biotec

IVD: this clone is used for *in vitro* diagnostics; RUO: suitable for research use only.
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